- Strategy
- Payers
- AI
- Cybersecurity
- Device Development
- Studies/Published Research
- Ethics
- Regulatory
- Digital Biomarkers
- Data Science
- Companion Diagnostics
- Clinical Care
- Digital Therapeutics
- Academic Research
- Virtual Reality
- RWE
- Digital Endpoints
- Medical Devices (Class II and Class III)
- Commercialization
- Clinical Trials
- Drug-Device Combinations
- SaMD
- Remote Patient Monitoring
- Patient Engagement
- Profiles/Q&A
FDA Grants Breakthrough Designation to Admetsys’ Automated Glucose and Continuous Blood Diagnostics System
This will allow the product to arrive in hospitals at a faster pace.
The FDA designated Admetsys Corporation’s automated glucose control and continuous blood diagnostics system as a breakthrough device. This allows Admetsys to accelerate the device’s timeline for being brought to market in the US.
Jeff Valk, Ceo of Admetsys, said in a press release, “The core of the system is its patient-adaptive learning algorithm. Machine intelligence using real-time biosensing data directly drives therapeutic actuation. This represents a new generation of device: fully autonomous clinical robotics."
The device is able to measure a patient’s blood for multiple analytes without any blood loss. It then uses this information to create a model of the patient’s metabolism and make recommendations for precise treatment levels of insulin and dextrose.
Valk continued, “The system unlocks a previously unachievable mode of care. It affects this economically, at scale, while preserving focus for clinicians. Precision automation fundamentally changes the equation."
